FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR 2026 ESMO TAT Honorary Award Recipient Announced Longer RFS with Nivolumab Than with Ipilimumab Among Patients with Resected Stage IIIB-C or Stage IV Melanoma Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC MOST POPULAR 9 Ways To Teach Kids To Be Confident (Without Teaching Them... October 24, 2019 Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with... September 6, 2024 9 Ways to Use Social Media for Support Throughout Your Cancer... February 4, 2021 FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma November 13, 2025 Load more HOT NEWS Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... Cancer Rehabilitation Starts at Diagnosis FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... EMA Recommends Extension of Indications for Pirtobrutinib
